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C

oronavirus disease 2019 (COVID-19) is caused by
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Gastrointestinal symptoms in COVID-19 are
being reported increasingly.1 Data on the involvement of
the pancreas in COVID-19 have been emerging, and
multiple case reports of SARS-CoV-2–induced acute
pancreatitis have been published in the literature.2
Angiotensin-converting enzyme-2 is the target receptor
of SARS-CoV-2 and is expressed abundantly by both the
exocrine and endocrine pancreatic tissues.3 The presence
of angiotensin-converting enzyme-2 in the pancreas could
make it susceptible to SARS-CoV-2, resulting in interstitial
leakage of pancreatic lipase, adipose tissue lipolysis, and
potentially toxic fatty acid–induced damage. These
changes can at least contribute to cytokine storm, multiorgan dysfunction, and COVID-19 morbidity.4 Due to its
nonspeciﬁcity, lipase could be elevated in a myriad of
conditions, such as infections, renal dysfunction,
medication-related, gastrointestinal, and hepatobiliary
disease.5 Given this, it is critical to evaluate the prevalence of hyperlipasemia in COVID-19 and predict clinical
outcomes.

Methods
We conducted a systematic search using PubMed, Embase,
Ovid, and Google Scholar databases from December 1, 2019 to
October 9, 2020, to evaluate hyperlipasemia in patients with
COVID-19. The following search terms were used: COVID-19,
SARS-CoV-2, lipase, pancreatic injury, and pancreas. The articles
with relevant data on the prevalence of hyperlipasemia and its
effect on COVID-19 severity were examined. All adult patients
with nasopharyngeal reverse transcription polymerase chain
reaction positive for SARS-CoV-2 were included in the analysis.
Severe COVID-19 was deﬁned as clinical deterioration resulting
in adverse clinical outcomes, such as admission to the intensive
care unit (ICU), need for mechanical ventilation, or death.
Hyperlipasemia was deﬁned as any elevation in lipase levels
above the upper limit of the normal reference level. The deﬁnition of hyperlipasemia varied among the studies because of
differences in the range of lipase levels, as did the deﬁnition of
severe COVID-19.

OpenMeta[Analyst] software was used to estimate the pooled
prevalence of lipase elevations among patients with COVID-19 and
the pooled odds ratio for severe COVID-19 among this subset of
patients. Results were reported with a 95% conﬁdence interval,
and a P value of <.05 was considered statistically signiﬁcant.
Heterogeneity was assessed using the I2 test, and I2 >50% was
taken as a measure of moderate inter-study variation.

Results
The initial search yielded 52 articles. After excluding
duplicates and review articles, 7 studies3,6-10 (6 retrospective observational studies and 1 prospective observational
study11) were included in the pooled analysis. A ﬂow chart
depicting the study screening and selection process is presented in Supplementary Figure 1.
Data on the point prevalence of hyperlipasemia were
available in all 7 studies, whereas only 4 reported clinical
outcomes, ICU admission status, and need for mechanical
ventilation or death. The normal range of serum lipase
levels differed among the studies. Although 4 studies had an
average upper limit of 50–60 U/L, 2 had a higher cutoff
(>300 U/L) for lipase levels. Data for 756 patients with
COVID-19 were reported in these studies, of which 92 had
hyperlipasemia. All of the studies were single-center experiences except two. Two studies deﬁned severe COVID-19 as
patients needing ICU admission, 1 study as a need for mechanical ventilation, and only 1 study used a combination of
all of the above three to deﬁne severe COVID-19.
Supplementary Table 1 outlines the baseline characteristics of the included studies.
The results of this pooled analysis are shown in
Figure 1A and B. Among 756 patients with COVID-19 with
available lipase levels, the pooled prevalence of hyperlipasemia was 11.7% (95% conﬁdence interval, 0.094–
0.140; P ¼ .001; I2 ¼ 0%). The pooled odds ratio for severe
COVID-19 in these patients was 3.143 (95% conﬁdence

Abbreviations used in this paper: COVID-19, coronavirus disease 2019;
ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
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Figure 1. (A) Pooled incidence rate of hyperlipasemia in patients with COVID-19. (B) Pooled odds ratio of severe COVID-19 in
patients with hyperlipasemia.

interval, 1.543–6.400; P ¼ .003); mild inter-study heterogeneity was observed (I2 ¼ 27%).

Discussion
Based on the results of our pooled analysis, hyperlipasemia was found in 11.7% of patients affected by SARSCoV-2. Patients with COVID-19 with hyperlipasemia are at
an approximately 3-fold higher risk of poor clinical outcomes, including need for ICU admission, mechanical
ventilation, or death.
Although multiple mechanisms have been proposed for
pancreatic injury in COVID-19, the exact etiology remains
unclear. Some of the mechanisms include direct pancreatic
tissue damage by SARS-CoV-2 and intense inﬂammatory
response (interleukin 1b, interleukin 6, and tumor necrosis
factors) with cytokine storm–mediated tissue injury.
Furthermore, studies found that patients with COVID-19
with pancreatic injury had a higher prevalence of severe
illness on admission; lower levels of CD3þ and CD4þ T cells;
and higher levels of aspartate aminotransferase, g-glutamyl
transferase, creatinine, lactate dehydrogenase, and erythrocyte sedimentation rate.6
Limitations of this study include a modest sample size
of 756 patients with COVID-19, of which 92 patients had

elevated serum lipase levels. The degree of hyperlipasemia
was not uniform across all studies. Potential confounders,
such as age, comorbidities, and medication use, could alter
the results of this study. Furthermore, a lack of highquality randomized controlled trials with adjustment for
potential confounders is a notable limitation. Given the
inclusion of observational studies, selection bias, information bias, and confounding bias are possible. The
prevalence of hyperlipasemia could be underestimated
due to a lack of testing and nonreporting of the data for
many patients.
Severe pancreatic injury resulting in acute pancreatitis
might not be a common event in COVID-19. As evidenced by
lipase elevation, mild to moderate pancreatic injury is a
clinically signiﬁcant ﬁnding in these patients. Future prospective studies are warranted to ascertain the exact impact
of lipase elevation in COVID-19 and guide management
strategies for these patients.

Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://doi.org/10.1053/
j.gastro.2020.10.037.
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Supplementary Figure 1. Study ﬂow chart.
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Supplementary Table 1.Baseline Characteristics of Included Studies With Hyperlipasemia in Coronavirus Disease 2019
First author

Type of study

Region

McNabb-Baltar7 Retrospective multicenter United States
cohort study

Sample size

Deﬁnition of hyperlipasemia
Male patients, n (serum lipase levels, U/L)

71
patients with COVID-19

32

>60

Retrospective cohort
single-center study

United States

1003 patients with
COVID-19; 83 with available
lipase levels

11

>3  ULN; >156

Liu3

Retrospective observational
multicenter study

China

121 patients with
COVID-19

75

>78

Aghemo9

Retrospective observational
single-center study

Italy

292 patients with COVID-19;
lipase levels available in
249 patients

199

>68

Wang6

Retrospective observational
single-center study

China

52 patients with COVID-19

24

>70

Bruno10

Retrospective observational
single-center study

Italy

70 patients with COVID-19

Not reported

>393

Pezzilli11

Prospective observational
single-center study

Italy

110 patients with COVID-19

69

>300

Barlass8

ULN, upper limit of normal.

